Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Sociedad Española de Farmacia Hospitalaria
2017
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876435362826420224 |
|---|---|
| author | Carla Bastida |
| author_facet | Carla Bastida |
| contents | Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population Carla Bastida Ana Grau Mónica Márquez Montse Tuset Elisa De Lazzari Esteban Martínez Josep María Gatell Medicina Aged Polypharmacy HIV infection Drug interactions Objective: Comorbidities associated with the ageing of the HIV+ population may require chronic treatment. Our aim is to determine the degree of polypharmacy and the number of potential drug-drug interactions, as well as the relationship between both variables in a HIV-infected population over the age of 65.Methods: Descriptive transversal study targeting HIV+ patients aged ≥65, attended in a Spanish hospital in 2014. The prevalence of polypharmacy (≥5 drugs) and potential drug-drug interactions were assessed, and also risk factors associated with such.Results: 265 subjects aged ≥65 years were identified, 197 of whom were on antiretroviral treatment and had data about their electronic prescription. 93% were polymedicated. The patients whose antiretroviral treatment included a non -nucleoside reverse transcriptase inhibitor (NNRTI) demonstrated a fourfold probability of being polymedicated. 65% of the patients showed at least one potential drug-drug interaction and 6.6% a severe potential drug-drug interaction. The risk of interaction was significantly associated with the number of prescribed drugs (incidence rate ratio per prescribed drug, CI 95%: 1.18 (1.14;1.22; p<0.0001) and with the use of protease inhibitors (PI) (incidence rate ratio, CI 95%: 1.65 (1.28;2.11; p=0.0001)).Conclusion: Polypharmacy has a high prevalence and is more common in patients treated with NNRTI. The number of potential drug-drug interactions increase with the number of prescribed drugs and is higher in those patients on PI. 2017 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962297007 https://www.redalyc.org/journal/3659/365962297007/ https://www.redalyc.org/journal/3659/365962297007/html/ https://www.redalyc.org/journal/3659/365962297007/365962297007.epub https://www.redalyc.org/journal/3659/365962297007/movil 10.7399/fh.10778 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.5 Vol.41 |
| format | Artículo científico |
| id | redalyc_365962297007 |
| institution | Redalyc |
| language | en |
| publishDate | 2017 |
| publisher | Sociedad Española de Farmacia Hospitalaria |
| spellingShingle | Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population Carla Bastida Medicina Aged Polypharmacy HIV infection Drug interactions Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population Carla Bastida Ana Grau Mónica Márquez Montse Tuset Elisa De Lazzari Esteban Martínez Josep María Gatell Medicina Aged Polypharmacy HIV infection Drug interactions Objective: Comorbidities associated with the ageing of the HIV+ population may require chronic treatment. Our aim is to determine the degree of polypharmacy and the number of potential drug-drug interactions, as well as the relationship between both variables in a HIV-infected population over the age of 65.Methods: Descriptive transversal study targeting HIV+ patients aged ≥65, attended in a Spanish hospital in 2014. The prevalence of polypharmacy (≥5 drugs) and potential drug-drug interactions were assessed, and also risk factors associated with such.Results: 265 subjects aged ≥65 years were identified, 197 of whom were on antiretroviral treatment and had data about their electronic prescription. 93% were polymedicated. The patients whose antiretroviral treatment included a non -nucleoside reverse transcriptase inhibitor (NNRTI) demonstrated a fourfold probability of being polymedicated. 65% of the patients showed at least one potential drug-drug interaction and 6.6% a severe potential drug-drug interaction. The risk of interaction was significantly associated with the number of prescribed drugs (incidence rate ratio per prescribed drug, CI 95%: 1.18 (1.14;1.22; p<0.0001) and with the use of protease inhibitors (PI) (incidence rate ratio, CI 95%: 1.65 (1.28;2.11; p=0.0001)).Conclusion: Polypharmacy has a high prevalence and is more common in patients treated with NNRTI. The number of potential drug-drug interactions increase with the number of prescribed drugs and is higher in those patients on PI. 2017 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962297007 https://www.redalyc.org/journal/3659/365962297007/ https://www.redalyc.org/journal/3659/365962297007/html/ https://www.redalyc.org/journal/3659/365962297007/365962297007.epub https://www.redalyc.org/journal/3659/365962297007/movil 10.7399/fh.10778 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.5 Vol.41 |
| title | Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population |
| topic | Medicina Aged Polypharmacy HIV infection Drug interactions |
| url | https://www.redalyc.org/articulo.oa?id=365962297007 https://www.redalyc.org/journal/3659/365962297007/ https://www.redalyc.org/journal/3659/365962297007/html/ https://www.redalyc.org/journal/3659/365962297007/365962297007.epub https://www.redalyc.org/journal/3659/365962297007/movil |